Correlation Between Oncopeptides and Diagonal Bio

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Oncopeptides and Diagonal Bio at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Oncopeptides and Diagonal Bio into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Oncopeptides AB and Diagonal Bio AB, you can compare the effects of market volatilities on Oncopeptides and Diagonal Bio and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Oncopeptides with a short position of Diagonal Bio. Check out your portfolio center. Please also check ongoing floating volatility patterns of Oncopeptides and Diagonal Bio.

Diversification Opportunities for Oncopeptides and Diagonal Bio

-0.38
  Correlation Coefficient

Very good diversification

The 3 months correlation between Oncopeptides and Diagonal is -0.38. Overlapping area represents the amount of risk that can be diversified away by holding Oncopeptides AB and Diagonal Bio AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Diagonal Bio AB and Oncopeptides is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Oncopeptides AB are associated (or correlated) with Diagonal Bio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Diagonal Bio AB has no effect on the direction of Oncopeptides i.e., Oncopeptides and Diagonal Bio go up and down completely randomly.

Pair Corralation between Oncopeptides and Diagonal Bio

Assuming the 90 days trading horizon Oncopeptides AB is expected to under-perform the Diagonal Bio. But the stock apears to be less risky and, when comparing its historical volatility, Oncopeptides AB is 2.6 times less risky than Diagonal Bio. The stock trades about -0.05 of its potential returns per unit of risk. The Diagonal Bio AB is currently generating about 0.01 of returns per unit of risk over similar time horizon. If you would invest  73.00  in Diagonal Bio AB on September 3, 2024 and sell it today you would lose (69.80) from holding Diagonal Bio AB or give up 95.62% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Oncopeptides AB  vs.  Diagonal Bio AB

 Performance 
       Timeline  
Oncopeptides AB 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Oncopeptides AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Diagonal Bio AB 

Risk-Adjusted Performance

7 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Diagonal Bio AB are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Diagonal Bio sustained solid returns over the last few months and may actually be approaching a breakup point.

Oncopeptides and Diagonal Bio Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Oncopeptides and Diagonal Bio

The main advantage of trading using opposite Oncopeptides and Diagonal Bio positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Oncopeptides position performs unexpectedly, Diagonal Bio can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Diagonal Bio will offset losses from the drop in Diagonal Bio's long position.
The idea behind Oncopeptides AB and Diagonal Bio AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Other Complementary Tools

Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments